Is it time for flexibility in botulinum inter-injection intervals?

Area of Science:

• Neurology
• Pharmacology

Background:

• Traditional recommendations for Botulinum neurotoxin (BoNT) injections favored infrequent administration at the lowest effective dose, based on older retrospective data.
• While BoNT is immunogenic, advancements in production have reduced immune resistance, meaning poor responses are often attributable to other causes.

Purpose of the Study:

• To evaluate the evidence supporting strict 90-day injection intervals for Botulinum neurotoxin (BoNT).
• To assess the efficacy and safety of flexible and shorter injection intervals for BoNT treatments.

Main Methods:

• Review of randomized controlled trials (RCTs) and long-term prospective studies on BoNT for cervical dystonia and blepharospasm.
• Analysis of retreatment rates and injection intervals in patients receiving various BoNT formulations.

Main Results:

• RCTs indicate that a significant percentage of patients require retreatment before 8 weeks or experience waning effects around 70 days.
• Long-term prospective studies using flexible intervals showed a substantial proportion of patients were reinjected between 6-12 weeks.
• Evidence suggests that factors other than immunogenicity are common causes of poor BoNT response.

Conclusions:

• The majority of current evidence does not support stringent adherence to 90-day BoNT injection intervals.
• Flexible and potentially shorter injection intervals may be appropriate for managing conditions like cervical dystonia and blepharospasm.
• Further long-term studies are needed to confirm the safety and efficacy of varied injection schedules while monitoring for immunogenicity.